Breaking News
The IRS and Another Multi-Billion-Dollar Mistake
Will The Collapse Of Credit Suisse Be Europe's "Lehman Brothers Moment"?
How to Efficiently Heat an Older Home -- And Save Money On Your Bills
Best Leaf Blower? EGO vs Milwaukee, Ryobi, DeWalt, Greenworks, Harbor Freight Atlas, Makita
Top Tech News
SpaceX's Starlink internet reaches Antarctica, touching all 7 continents
It's Insane. My Solar Generates up to 180kWh in a Day + Passive Solar Greenhouse Tour
'World's Most Advanced' Humanoid Robot Promises Not To 'Take Over The World'
Do Authoritarians 'Care' About You?
DARPA Vertical Takeoff and Landing X-Plane
Biden is blocking DeSantis from letting Floridians access cheaper medication
How salt and sand could replace lithium batteries
Quantum Heat Pump Made From Particles of Light
Three Eras of Machine Learning and Predicting the Future of AI
Outrageous armored submarine claims 50-km/h underwater top speed
DARPA Nucleic Technology Funded to Get Virus Response to 1-60 Days
The P3 teams are developing technologies to deliver antibodies using nucleic acid technology, and achieve sufficient serum concentrations of the antibodies for protection against the pathogen within three days after administration.
DARPA has programs for Pandemic Prevention Platform, Nucleic Acids On-Demand Worldwide (NOW), and PReemptive Expression of Protective Alleles and Response Elements (PREPARE) programs.
Nucleic Acids On-Demand Worldwide (NOW)
The goal of the NOW program is to develop a mobile medical countermeasure (MCM) manufacturing platform for use in stabilization and humanitarian operations to produce, formulate, and package hundreds of doses of nucleic acid therapeutics (DNA and/or RNA) in less than 24 hours. The developed platform should be a resilient, mobile, readily accessible nucleic acid MCM manufacturing capability that enables immediate threat response anywhere the military operates with minimal user intervention.